As human uricase has been silenced during evolution, counterparts from other species become an alternative for the treatment of hyperuricemia. Candida uricase is a promising option among them, but its aggregation propensity remains a major obstacle to clinical use. In this study, we designed two mutations according to homology-modeled 3D structure of Candida uricase: Cys249Ser substitution and C-terminal Leu deletion. The wild-type uricase and three mutants containing either or both of the mutations were expressed in Escherichia coli BL21 and validated by mass spectrometry. Size-exclusion chromatography and electrophoresis analysis demonstrated that aggregation was induced by interchain disulfide bonds and could be significantly avoided by Cys249Ser substitution. In combination with Cys249Ser substitution, deletion of Leu increased the enzymatic activity by 8%. Taken together, mutant containing both mutations is chosen as our target protein which is comparatively more suitable for therapeutic use. In addition, homology-modeled 3D structure was proved to be an efficient approach for protein engineering.
Introduction
Uricase (EC 1.7.3.3) is a peroxisomal enzyme involved in purine metabolism, which converts uric acid (UA) to allantoin that is easily excreted by the kidney (Sarma et al., 1999) . But as a result of multiple independent evolutionary events, the uricase gene in higher primates, including human, is silenced or pseudogenized (Kratzer et al., 2014) . As a consequence, UA levels are 3-10 times higher in human than in other mammals possessing a functional uricase, which may lead to hyperuricemia. And hyperuricemia can result in urate precipitation with the formation of crystals that are involved in gout, tumor lysis syndrome (TLS), chronic kidney disease and various cardiovascular diseases.
Currently, available anti-hyperuricemia drugs include uricosuric agents that promote UA excretion and inhibitors of xanthine oxidase (XO) that block urate formation (Abhishek et al., 2017; Dalbeth et al., 2016) . Probenecid is a well-established hypouricemic agent acting on the renal urate transporter, but it is not widely used due to the associated kidney and liver toxicity. Allopurinol and febuxostat are XO inhibitors and could only be used for particular hyperuricemia-associated diseases because of drug toxicity and tolerance (Richette and Bardin, 2010; Yasu et al., 2016) . Uricase is a unique anti-hyperuricemia drug acting on urate and is effective in diverse forms of hyperuricemia in virtue of removing pre-existing urate crystals in joints (Schlesinger et al., 2011) with negligible drug-drug interactions (Malaguarnera et al., 2009 ).
Up to date, there are two kinds of uricase that have been approved for the management of plasma UA level: rasburicase and pegloticase. Rasburicase is indicated for the prevention and treatment of TLS which can be a potentially life-threatening emergency (Campara et al., 2009; Knoebel et al., 2011) . Though it is significantly more effective than conventional drugs (Tatay et al., 2010) , the enthusiasm for its use has been dampened by serious allergic reactions (Allen et al., 2015; Cheuk et al., 2017) . Pegloticase is a medication for the treatment of severe, treatment refractory, chronic gout. As a polyethylene glycol-conjugated form of uricase, pegloticase has elevated thermal stability (Tian et al., 2013) and longer serum half-life, but has a high discontinuation rate (30-50%) due to development of anti-drug antibodies with the resultant loss of efficacy and risk of infusion reactions (Garay et al., 2012; Baraf et al., 2014; Verhoef et al., 2014) . All of these adverse effects are associated with immunogenicity, which is considered as a major challenge for therapeutic proteins.
Immunogenicity is caused by diverse interacting factors including intrinsic causes such as specific amino acid sequence (King et al., 2014; Mazor et al., 2016) , post-translational modifications (Jefferis, 2016; Kuriakose et al., 2016; Reusch and Tejada, 2015) and extrinsic factors including route of administration, dosage and, in particular, the patients' genetic profile (Hershfield et al., 2014) . At present, there is a common consensus that one of the highest risk factors for drug immunogenicity is the property of proteins to aggregate (Deehan et al., 2015) . Even the presence of sub-visible nano-and microparticles may be immunogenic. However, aggregation mechanisms are highly complex and the investigation requires experimental efforts, manpower and material cost. Some in silico methods using conformational flexibility, electrostatic and hydrophobic protein surface properties are supposed to be best suited for prediction of protein aggregation (Marczak et al., 2016; Galm et al., 2017) .
Existing in the form of non-covalent homotetramer, most uricases are easier to aggregate than normal monomeric proteins (Caves et al., 2013; Gruia et al., 2017) . In order to obtain a Candida uricase with improved polymerization state, which may be a promising option for therapeutic use, we performed homology modeling by SWISS-MODEL (Arnold et al., 2006; Biasini et al., 2014) . Two mutations that may decrease aggregation were designed and mutants containing either or both of them were expressed and analyzed to evaluate their influence.
Materials and methods

Homology modeling of 3D structure
Amino acid sequence of the uricase was obtained from GenBank (BAA06804.1). The 3D structure was simulated by the SWISS-MODEL server (http://swissmodel.expasy.org/) using uricase from Aspergillus flavus (PDB ID: 4d12) (Bui et al., 2014) as a template, which had a high homology identity (65.93%) with it. Subsequently, the constructed model was exported and submitted to Swiss-PdbViewer for energy minimization. In addition, quality of the model was evaluated by RAMPAGE (http://mordred.bioc.cam. ac.uk/~rapper/rampage.php) and ProSA (https://prosa.services.came. sbg.ac.at/prosa.php).
Protein expression and purification
In this study, the wild-type Candida uricase and three mutants were expressed. The genes were obtained by de novo synthesis and verified by DNA sequencing. The amplified genes were digested with NdeI/XhoI endonucleases and cloned into pET-22b (+) via NdeI and XhoI sites, which yielded the recombinant plasmids. Escherichia coli BL21 harboring the recombinant plasmid was cultured in LuriaBertani medium containing 100 μg/ml ampicillin at 37°C until the A600 reached 0.8. Protein expression was induced at 22°C with the addition of isopropyl β-D-thiogalactopyranoside (IPTG) to a final concentration of 0.2 mM for 14 h. The bacteria collected by centrifugation were crushed using ultrasonic for 5 min at a power of 400 W, and the supernatants were crude enzymes, which were then subjected to an AKTA FPLC (GE Healthcare, Uppsala, Sweden) with a HiTrap Q FF column (GE Healthcare, Uppsala, Sweden) conditioned with 10 bed volumes of 20 mM Tris-hydrochloride (TrisHCl) (pH 8.0) for ion exchange purification. After subsequent being washed with 20 mM Tris-HCl (pH 8.0) containing 100 mM sodium chloride (NaCl), the proteins were eluted and collected. The protein solutions were then concentrated with ultrafiltration devices and subjected to a Superdex 200 increase 10/300 GL column (GE Healthcare, Uppsala, Sweden) for gel filtration purification using 20 mM Tris-HCl (pH 8.0) containing 100 mM NaCl as elution buffer. Monitored by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), the main peak fractions containing wildtype uricase or mutants were collected.
Electrophoresis analysis
Purity and apparent molecular weight were evaluated by SDS-PAGE performed on a 12% Tris-glycine gel. Samples were diluted in reducing or non-reducing sample buffer and heated at 95 ± 5°C for 5 min and 10 μg of each sample was loaded onto the gel. The samples were separated by electrophoresis and the gel was stained with 0.25% w/v Coomassie R-250, destained to clarity, and scanned.
Protein validation by mass spectrometry
The three proteins were further confirmed by the Acquity UPLC system connected online to a Xevo G2-S mass spectrometer (Waters Corporation, Milford, MA, USA). For intact protein analysis, the column was a Waters BEH300 C4 column (2.1 mm × 50 mm, 1.7 μm particle). The flow rate was 0.2 ml/min using a gradient from 5% to 50% Solvent B (Solvent B of 100% acetonitrile with 0.1% formic acid, Solvent A of 0.1% formic acid in water) in 7 min at a column temperature of 35°C. The scan range of mass spectrometric was m/z 500-3000. Data were acquired and processed using UNIFI 1.6 (Waters Corporation, Milford, MA, USA).
Size-exclusion chromatography analysis
The column was a Phenomenex Yara 3 u SEC-2000 column (300 mm × 7.8 mm). The flow rate was 0.5 ml/min using an elution buffer of 20 mM Tris-HCl containing 100 mM NaCl (pH 7.0). In order to determine the molecular masses of protein polymers, a multi-angle laser light scatter (MALLS, Dawn Heleos, Wyatt Technology Corporation, Santa Barbara, CA, USA) was also connected online to size exclusion chromatography (SEC). For causal analysis of polymerization, samples had been exposed to 37 ± 1°C for 20 h were incubated with dithiothreitol (DTT) with a final concentration of 25 mM for 1 h at 37°C, and then retested by SEC.
Circular dichroism spectroscopy
The circular dichroism (CD) spectra were recorded in a 1.0 cm quartz cell at room temperature using a Jasco J-810 spectropolarimeter. The spectra are an average of three consecutive scans from 240 to 193 nm, recorded with a band width of 1 nm, a time constant of 16 s and a scan rate of 100 nm/min. Spectra were recorded and corrected by subtracting background contributions of blank samples.
Enzymatic activity analysis
Uricase activity was measured in 100 mM phosphate buffer with pH 7.0. Uricase with a final concentration of 1 μg/ml was incubated with 180 μM UA at 37°C. The depletion of UA was measured by ultraviolet absorption at 293 nm every 10 s for a period of 10 min using a SpectraMax reader (Molecular Devices Corporation, Sunnyvale, CA, USA). The rate of UA degradation (R ΔUA , μM/min) was calculated by SoftMax Pro software (Molecular Devices Corporation, Sunnyvale, CA, USA). One unit (U) was defined as the amount of enzyme necessary to transform 1 μM of UA into allantoin in 1 min at 37°C and pH 7.0. The specific activity (A S ) was enzymatic activity per milligram of uricase, which was calculated as follows:
In the equation, M represented for the amount uricase which was expressed in milligram, therefore, the A S could be expressed in μmol min
.
Statistical analysis
All data were expressed as the mean ± standard deviation. Statistical analysis was performed with Student's t-test. A P-value <0.05 was considered statistically significant.
Results
Homology modeling of 3D structure and designing mutations
The 3D structure of Candida uricase was modeled by SWISS-MODEL with a Global Model Quality Estimation (GMQE) score of 0.79 and a Qualitative Model Energy ANalysis (QMEAN) Z-score of −1.44, which indicated that the model had an acceptable reliability. Results of RAMPAGE and ProSA also showed the good quality of the model (Fig. 1A and B ). In this model, two Cys residues in each monomer, Cys167 and Cys249, were located on the surface of tetramer (Fig. 1C) . For their steric accessibility, the two residues may participate in the formation of interchain disulfide bonds and lead to protein aggregation. As was reported that the mutation of Cys167 could decrease the uricase activity (Koyama et al., 1996) , we determined to substitute Cys249 with Ser only. 3D structure of uricase colored on the basis of hydrophobicity showed that the surface of tetramer was occupied by hydrophilic residues except for the C-terminal region of each subunit, at the end of which a hydrophobic Leu was located (Fig. 1D) . The C-terminal Leu may be involved in hydrophobic interactions between homotetramers, causing non-covalent polymerization of uricase. Accordingly, deletion of C-terminal Leu was set as another mutation.
Taken together, we designed two mutations: Cys249Ser substitution and deletion of C-terminal Leu, and three mutants containing either or both of them will be subsequently expressed, and designated as 'ΔL302', 'C249S' and 'ΔL302 & C249S', respectively.
Preparation and validation of wild-type uricase and mutants
The recombinant plasmids were successfully constructed and transformed into E. coli BL21 and the expression of candidate proteins was induced with IPTG. After being purified by ion exchange and gel filtration chromatography, wild-type uricase and three mutants with purity over 95% were obtained ( Fig. 2A) . Intact protein analysis showed that the observed molecular masses were all consistent with theoretical values (Fig. 2B) . Finally, the purified proteins were aliquoted and stored at −70°C.
Polymerization analysis
SEC analysis showed that high-molecular mass (MW) multimers were formed in wild-type uricase and 'ΔL302' after being incubated at 37°C, and the proportion of which increased with time. In contrast, no high-MW multimers were formed in 'C249S' and 'ΔL302 & C249S' through the same treatment (Fig. 3A) . According to MWs measured by SEC-MALLS, the natural form of uricase was tetramer, and the newly formed multimers were higher order ones such as octamers (Fig. 3B) . The higher order multimers could be reduced to tetramers according to SEC (Fig. 3C) . When tested by SDS-PAGE, as non-covalent interactions were destroyed by SDS, monomers and dimers appeared instead of tetramers and higher order multimers, and the dimers could also be reduced to monomers (Fig. 3D) . These results proved that the formation of interchain disulfide bonds was the main inducing factor for aggregation, and C249S substitution significantly improved the aggregation state of uricase.
It is notable that the proportion of higher order multimers or dimers was larger in 'ΔL302' than that in wild-type uricase (Fig. 3C  and D) , which implied that deletion of Leu promoted the formation of them. But when Cys249 was substituted with Ser, deletion of Leu had no effect on polymerization (Fig. 3A) . In addition, the proportion of higher order multimers measured by SEC was larger than that of dimers measured by SDS-PAGE in both wild-type uricase and 'ΔL302' (Fig. 3C and D) , which meant that not all subunits of tetramers participated in the formation of interchain disulfide bonds.
CD analysis
The CD analysis was used to reveal changes of secondary structure. The spectra of all samples were consistent with each other (Fig. 3E) , which indicated that neither the two mutations nor the polymerization had any effect on secondary structure. Results showed that the specific activity of wild-type uricase decreased to 90% after exposed to 37°C for 20 h (Fig. 4) , in which the ratio of multimers was 30% (Fig. 3C) , then an equation could be deduced as follows: In the equation, A M represents for specific activity of multimers, and A T represents for specific activity of tetramers, and A M was 67% of A T by calculation, which meant that the specific activity of multimers decreased to 67% in wild-type uricase. In contrast, 'ΔL302' preserved its activity after the same treatment (Fig. 4) , despite having a larger proportion (58%) of multimers (Fig. 3C) , which indicated that multimers of 'ΔL302' had similar activity to tetramers. These results suggested that the deletion of Leu helped uricase multimers to preserve enzymatic activity. In addition, 'ΔL302' and 'ΔL302 & C249S' had improved specific activities (6% and 8%) compared with wild-type uricase and 'C249S', respectively (Fig. 4) , which indicated that deletion of Leu increased uricase tetramers's specific activity. What's more, by comparing the specific activity of wild-type uricase with 'C249S', and 'ΔL302' with 'ΔL302 & C249S', we found that there was no significant difference between them (Fig. 4) , and, therefore, C249S substitution had no effect on enzymatic activity.
Discussion
As uricases from terrestrial vertebrates are insoluble (Hruban and Swift, 1964; Usuda et al., 1988; Hayashi et al., 2000) , more groups focus on fungal uricases which are soluble and exhibit comparatively high catalytic activity (Ravichandran et al., 2015; Shaaban et al., 2015; Kotb, 2015) , but instability remains a major obstacle to their therapeutic or diagnostic use. Various methods were tested to improve stability, such as inducing disulfide bonds (Hibi et al., 2016) , using novel delivery platform (Zhang et al., 2015; Gil et al., 2017) and searching for new microorganisms with ideal uricase (Kotb, 2015) . In this study, our efforts are focused on reducing aggregation by inhibiting the formation of interchain disulfide bonds and decreasing hydrophobic interactions.
Disulfide bonds play an important role in stabilizing protein structure, but incorrect disulfide bonds may lead to protein aggregation or degradation. In the natural homotetramer of Candida uricase, no disulfide bond is formed. However, heat treatment (60°C for 15 min) could cause the formation of disulfide bonds and lead to decrease of uricase activity (Koyama et al., 1996) . In this study, we proved that Cys249 was the key amino acid residue for the formation of interchain disulfide bonds, which was consistent with the prediction of modeled 3D structure. As the results showed, C249S substitution could improve the protein's aggregation state with no effect on its enzymatic activity; therefore, it is an advantageous mutation.
On the other hand, we designed the deletion of C-terminal Leu in the purpose of reducing hydrophobic interactions between homotetramers so as to prevent polymerization, but the results revealed that it promoted the formation of higher order multimers. Fortunately, together with the C249S substitution, it had no effect on polymerization state and improved the protein's enzymatic activity. In combination with C249S substitution, deletion of Leu is also considered as a beneficial mutation. Accordingly, we choose mutant 'ΔL302 & C249S' as our target protein that has improved polymerization state and enzymatic activity.
In summary, we obtained a novel mutant of Candida uricase with comparatively better attributes for therapeutic use. In the course of research, homology modeling of 3D structure was proved to be an efficient approach for protein engineering, but the designs should be validated by experiments.
